Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) - A meeting report of the WHO Programme for Vaccine Development

By Crowe J.E.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 415-421

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection

By Piedra P.A.   Glezen W.P.   Kasel J.A.   Welliver R.C.   Jewel A.M.   Rayford Y.   Hogerman D.A.   Hildreth S.W.   Paradiso P.R.  

Vaccine, Vol. 13, Iss. 12, 1995-08 ,pp. : 1095-1101

Elsevier

Access to resources Recommend Favorite

The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B

By Power U.F.   Plotnicky H.   Blaecke A.   Nguyen T.N.  

Vaccine, Vol. 22, Iss. 2, 2003-12 ,pp. : 168-176

Elsevier

Access to resources Recommend Favorite

Immune response to baculovirus expressed protein fragment amino acids 190-289 of respiratory syncytial virus (RSV) fusion protein

By Werle B.   Bourgeois C.   Alexandre A.   Massonneau V.   Pothier P.  

Vaccine, Vol. 16, Iss. 11, 1998-07 ,pp. : 1127-1130

Elsevier

Access to resources Recommend Favorite

Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsiveness

By Miller M.   Cho J.Y.   Baek K.J.   Castaneda D.   Nayar J.   Rodriguez M.   Roman M.   Raz E.   Broide D.H.  

Vaccine, Vol. 20, Iss. 23, 2002-07 ,pp. : 3023-3033

Elsevier

Access to resources Recommend Favorite